MONASH IVF GROUP LIMITED — Director's Dealing 2017

Nov 15, 2017

==> picture [596 x 93] intentionally omitted <==

ASX Announcement

Monash IVF Group Limited (ASX: MVF)

16 November 2017

APPENDIX 3Y NOTICE

An Appendix 3Y by MVF ( Monash IVF ) for James Thiedeman, former CEO of Monash IVF, is attached.

Monash IVF advises that:

1. the delay in lodgement of the Appendix 3Y Notice was due to an internal administrative oversight. Upon being identified by Monash IVF, the notice has been immediately lodged.

2. Monash IVF and its directors are aware of their obligations under ASX Listing Rule 3.19A. Each director is made aware of this obligation pursuant to their terms of appointment. In addition, Monash IVF's Securities Trading Policy includes the requirement that all directors must notify the Company Secretary of any dealings in Monash IVF's securities within 2 business days of such dealing occurring.

3. Monash IVF's existing arrangements are considered adequate and the late lodgement of this particular Appendix 3Y notice was an isolated incident. Monash IVF is mindful of its disclosure obligations under ASX Listing Rule 3.19A.2. The directors are also aware of their personal obligation involving Monash IVF's securities.

Michael Knaap Chief Financial Officer & Company Secretary Monash IVF Group Limited Tel: +61 (0) 3 9420 8235

About Monash IVF Group

Monash IVF Group is a leading provider of assisted reproductive services and specialist womens imaging and diagnostic services in Australia and Malaysia. The Group is a driving force in the development of assisted reproductive technologies and has many Australian and world firsts since the work of our pioneers who achieved the first IVF pregnancy in the world in 1973.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Monash IVF Group Limited

ABN 90 169 302 309

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Note that this appendix 3Y notice updates the Appendix 3Y notice lodged on 11 August 2014 and now includes Part 3

Name of Director	Benjamin James Thiedeman
Date of last notice	22 September 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Direct or indirect interest	Direct or indirect interest	Direct	Direct	Direct
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
	Date of change		04/10/2017
	No. of securities held prior to change		850,758 Ordinary Shares800,000 Options
			800,000 Opti	ons
	Class		Ordinary Sha	res and Options
	Number acquired		Nil
	Number disposed		660,000 Opti	ons lapsed
	Value/Consideration		n/a
	Note: If consideration is non-cash, provide details anvaluation	d estimated
	No. of securities held after change		850,758 Ordin	ary Shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back

Monash IVF Group Limited (“MVF”)announces the vesting of 140,000 unlistedoptions issued under MVF’s Long TermIncentive Plan (“Plan”) held by Mr JamesThiedeman.Following testing of the earning per sharegrowth hurdle in accordance with the termsof the Plan, MVF has determined that140,000 unlisted Tranche 1 options issuedunder the Plan (“Options”) have vested andare exercisable and that 260,000 Tranche 1Options have lapsed.Following testing of the total shareholderreturn hurdle in accordance with the termsof the Plan, MVF has determined that400,000 Tranche 2 Options have lapsed.As Mr Thiedeman became a Leaver underthe Plan on 10 November 2017, the140,000 Tranche 1 Options may beexercised in accordance with the terms ofthe Plan at any time prior to 5.00pm 8December 2017 - 28 days after the date hebecame a Leaver.This notice is given for the purposes ofASX ListingRule3.10.7

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder(if issued securities)	n/a
Date of change	n/a
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	n/a
Interest acquired	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	n/a
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	n/a
Interest after change	n/a

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	n/a
If so, was prior written clearance provided to allow the tradeto proceed during this period?	n/a
If prior written clearance was provided, on what date was thisprovided?	n/a

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3